Our findings suggest that inhibiting CSF‐1R signalling as previously proposed as a potential therapeutic for AD (Dagher et al, 2015; Spangenberg et al, 2019) could in fact exacerbate the human pathology. The gene discussed is CSF1R; the disease is Alzheimer disease.